We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

New Low-Cost COVID-19 Ventilator Could Resolve Mechanical Ventilators Shortage in Developing Countries

By HospiMedica International staff writers
Posted on 06 Oct 2021
Print article
Image: Low cost emergency ventilator to tackle coronavirus designed by Imperial team (Photo courtesy of Imperial College London)
Image: Low cost emergency ventilator to tackle coronavirus designed by Imperial team (Photo courtesy of Imperial College London)

A new low-cost ventilator design invented during COVID-19 could address the global shortage of ventilators for other respiratory diseases.

The ventilators designed by scientists from the Imperial College London (London, UK) are required by patients in intensive care units (ICU) who are seriously ill with respiratory diseases like COVID-19, flu, and tuberculosis, and are both simpler and cheaper to make than the currently available ventilators. Now, the creators of the designs hope that their promising technology, initially developed for emergency short-term ventilators in response to the coronavirus pandemic, will help to address the shortage of mechanical ventilators in developing countries in the long term.

The researchers behind the ‘RELAVENT’ ventilator (previously known as JAMVENT), have demonstrated that the design achieves all of the performance requirements set out in ISO 80601, the international standard for critical care ventilators. The team also showed that the system performs equally well with a home-use oxygen concentrator as with pressurized gas supplies like those found in hospitals. The researchers have published the designs of the prototype and details of the rigorous testing required for regulatory approval. They hope that following funding and approval as a medical device, the ventilators can be used in low-and-middle income countries (LMICs) and newly emerging economies (NEEs), which suffer from an historical long-term shortage of ventilators. The next step towards approval as a medical device will be development from the advanced prototype stage to a mass-manufacturable medical device, which must be carried out under special regulatory conditions.

“Our ventilators are inspired by the beauty of simplicity. Rather than using the complex control valves used in most ventilators, we conceived a way to use simple on-off valves to provide the high-level performance required of ICU ventilators. This way, we have made the technology much cheaper and less expensive to make and maintain,” said lead researcher Dr. Joseph van Batenburg-Sherwood, of Imperial College London’s Department of Bioengineering.

“We are keen to bring our ventilator to as many hospitals as possible to combat serious respiratory diseases worldwide. We have the right technology to help address this unmet medical need and hope to attract investment to help take it further,” added Professor James Moore, Director of Translation for Imperial’s Department of Bioengineering.

Related Links:
Imperial College London

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
12-Channel ECG
CM1200B
New
Anesthesia Cart
UTGSU-333369-DKB
New
Medical Cart
Medical Carts

Print article

Channels

Critical Care

view channel
Image: A mechanosensing-based approach offers a potential path to the treatment for cardiac fibrosis (Photo courtesy of Adobe Stock)

Mechanosensing-Based Approach Offers Promising Strategy to Treat Cardiovascular Fibrosis

Cardiac fibrosis, which involves the stiffening and scarring of heart tissue, is a fundamental feature of nearly every type of heart disease, from acute ischemic injuries to genetic cardiomyopathies.... Read more

Surgical Techniques

view channel
Image: Bioprinting synthetic vasculature could dramatically change how cardiovascular diseases are treated (Dell, A.C., Maresca, J., Davis, B.A. et al.; doi.org/10.1038/s41598-025-93276-y)

Bioprinted Aortas Offer New Hope for Vascular Repair

Current treatment options for severe cardiovascular diseases include using grafts made from a patient's own tissue (autologous) or synthetic materials. However, autologous grafts require invasive surgery... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more